Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 71.48% is in line with its 5-year average of 70.09%, near the high end of its 5-year range (53.44%–74.74%).
0.01% below its 12-month average of 71.49%.
Reported quarterly gross margin; no daily interpolation.
GROSS MARGIN
71.48%
GROSS MARGIN AVG TTM
71.49%
GROSS MARGIN AVG 3Y
69.70%
GROSS MARGIN AVG 5Y
70.09%
GROSS MARGIN AVG 10Y
71.93%
GROSS MARGIN AVG 15Y
73.81%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.01%
CURRENT VS 3Y AVG
+2.55%
CURRENT VS 5Y AVG
+1.99%
CURRENT VS 10Y AVG
-0.63%
CURRENT VS 15Y AVG
-3.16%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
58.99%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+21.16%
vs the sector median at left
Market Cap
$366.74B
Gross Margin
75.38%
TTM Avg
74.15%
3Y Avg
73.03%
5Y Avg
71.89%
Market Cap
$364.02B
Gross Margin
22.49%
TTM Avg
20.43%
3Y Avg
22.48%
5Y Avg
23.36%
Market Cap
$344.74B
Gross Margin
73.73%
TTM Avg
73.81%
3Y Avg
73.64%
5Y Avg
72.52%
Market Cap
$648.55B
Gross Margin
70.45%
TTM Avg
70.92%
3Y Avg
69.98%
5Y Avg
69.30%
Market Cap
$224.09B
Gross Margin
40.37%
TTM Avg
39.50%
3Y Avg
40.36%
5Y Avg
43.54%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $439.68B | 71.48% | 71.49% | 69.70% | 70.09% |
| Merck & Co., Inc. (MRK)vs › | $366.74B | 75.38% | 74.15% | 73.03% | 71.89% |
| UnitedHealth Group Incorporated (UNH)vs › | $364.02B | 22.49% | 20.43% | 22.48% | 23.36% |
| Roche Holding AG (RHHBY)vs › | $344.74B | 73.73% | 73.81% | 73.64% | 72.52% |
| AstraZeneca PLC (AZN)vs › | $248.20B | 81.88% | 81.51% | 79.26% | 77.31% |
| Johnson & Johnson (JNJ)vs › | $648.55B | 70.45% | 70.92% | 69.98% | 69.30% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.09B | 40.37% | 39.50% | 40.36% | 43.54% |
| Amgen Inc. (AMGN)vs › | $212.20B | 72.65% | 66.16% | 69.53% | 71.51% |
| Novo Nordisk A/S (NVO)vs › | $200.54B | 80.64% | 82.83% | 83.54% | 83.48% |
| Abbott Laboratories (ABT)vs › | $182.59B | 56.80% | 53.17% | 51.86% | 51.92% |
Gross Margin
71.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 74.74% |
| 2026-03-31 | 71.88% |
| 2025-12-31 | 72.61% |
| 2025-09-30 | 66.38% |
| 2025-06-30 | 71.82% |
| 2025-03-31 | 70.01% |
| 2024-12-31 | 70.89% |
| 2024-09-30 | 70.87% |
| 2024-06-30 | 70.94% |
| 2024-03-31 | 66.74% |
| 2023-12-31 | 60.11% |
| 2023-09-30 | 53.44% |
| 2023-06-30 | 69.42% |
| 2023-03-31 | 67.39% |
| 2022-12-31 | 72.42% |
| 2022-09-30 | 66.10% |
| 2022-06-30 | 71.41% |
| 2022-03-31 | 70.07% |
| 2021-12-31 | 70.98% |
| 2021-09-30 | 69.39% |
| 2021-06-30 | 67.60% |
| 2021-03-31 | 67.62% |
| 2020-12-31 | 66.20% |
| 2020-09-30 | 60.86% |
| 2020-06-30 | 64.40% |
| 2020-03-31 | 77.47% |
| 2019-12-31 | 76.95% |
| 2019-09-30 | 77.36% |
| 2019-06-30 | 77.96% |
| 2019-03-31 | 78.36% |
| 2018-12-31 | 75.65% |
| 2018-09-30 | 77.72% |
| 2018-06-30 | 76.64% |
| 2018-03-31 | 75.71% |
| 2017-12-31 | 70.54% |
| 2017-09-30 | 76.90% |
| 2017-06-30 | 78.00% |
| 2017-03-31 | 75.28% |
| 2016-12-31 | 77.12% |
| 2016-09-30 | 76.62% |
| 2016-06-30 | 78.22% |
| 2016-03-31 | 77.02% |
| 2015-12-31 | 76.95% |
| 2015-09-30 | 80.37% |
| 2015-06-30 | 83.27% |
| 2015-03-31 | 81.31% |
| 2014-12-31 | 79.48% |
| 2014-09-30 | 78.20% |
| 2014-06-30 | 77.41% |
| 2014-03-31 | 75.89% |
| 2013-12-31 | 74.92% |
| 2013-09-30 | 76.56% |
| 2013-06-30 | 77.54% |
| 2013-03-31 | 73.37% |
| 2012-12-31 | 75.69% |
| 2012-09-30 | 77.51% |
| 2012-06-30 | 76.12% |
| 2012-03-31 | 72.30% |
| 2011-12-31 | 75.82% |
| 2011-09-30 | 73.95% |
| 2011-06-30 | 74.09% |
| 2011-03-31 | 69.02% |
